Geron Corp

GON

Company Profile

  • Business description

    Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

  • Contact

    919 East Hillsdale Boulevard
    Suite 250
    Foster CityCA94404
    USA

    T: +1 650 473-7700

    E: [email protected]

    https://www.geron.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    258

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,173.5031.00-0.34%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,637.60370.95-1.55%
NASDAQ25,136.27229.82-0.91%
Nikkei 22561,142.35322.990.53%
NZX 50 Index14,224.3650.680.36%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,048.9033.30-0.37%
SSE Composite Index3,634.3521.48-0.59%

Market Movers